You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

Drug Price Trends for MOEXIPRIL HCL


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for MOEXIPRIL HCL

Average Pharmacy Cost for MOEXIPRIL HCL

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
MOEXIPRIL HCL 15 MG TABLET 00093-5150-01 0.91824 EACH 2025-01-22
MOEXIPRIL HCL 7.5 MG TABLET 00093-0017-01 0.90311 EACH 2025-01-22
MOEXIPRIL HCL 15 MG TABLET 68462-0208-01 0.91824 EACH 2025-01-22
MOEXIPRIL HCL 7.5 MG TABLET 68462-0209-01 0.90311 EACH 2025-01-22
MOEXIPRIL HCL 15 MG TABLET 00093-5150-01 0.88441 EACH 2024-12-18
MOEXIPRIL HCL 7.5 MG TABLET 68462-0209-01 0.92984 EACH 2024-12-18
MOEXIPRIL HCL 15 MG TABLET 68462-0208-01 0.88441 EACH 2024-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Moexipril HCL

Introduction to Moexipril HCL

Moexipril HCL, an angiotensin-converting enzyme (ACE) inhibitor, is used primarily in the treatment of hypertension. It is available as a generic medication and also under the brand name Univasc. Here, we will delve into the market analysis and price projections for Moexipril HCL.

Market Size and Growth

The global Moexipril market has shown steady growth in recent years. As of 2023, the market was valued at US$ 102 million and is anticipated to reach US$ 128.9 million by 2030, witnessing a Compound Annual Growth Rate (CAGR) of a significant percentage[3].

Market Competition

The Moexipril HCL market is characterized by competition among various pharmaceutical companies. The generic version of Moexipril HCL, produced by companies like Glenmark Pharmaceuticals, competes with the brand version, Univasc. The market competition is further influenced by the presence of other ACE inhibitors and Angiotensin II Receptor Blockers (ARBs)[2].

Pricing and Cost Savings

The pricing of Moexipril HCL varies significantly depending on the source and any available discounts. Here are some key price points:

  • Retail Price: The typical cash price for Moexipril HCL can range from $48.19 to $94.19 per 30 tablets of 15mg each, depending on the pharmacy[1][2].
  • Discounted Prices: Using coupons or discount cards, such as those from SingleCare or GoodRx, can reduce the cost dramatically. For example, with a SingleCare card, the price can be as low as $15.44 for 30 tablets of 15mg each[1][2].

Market Dynamics

Supply and Demand

The demand for Moexipril HCL is driven by the prevalence of hypertension and the need for effective antihypertensive medications. The supply side is influenced by the production capacity of pharmaceutical companies and the regulatory environment. The global supply and consumption of Moexipril HCL are expected to grow, driven by increasing healthcare needs and expanding market reach[4].

Economic Impact

The macroeconomic environment plays a crucial role in the Moexipril HCL market. Economic stability and healthcare policies can affect the affordability and accessibility of the medication. For instance, changes in healthcare policies or economic downturns can impact the market size and growth rate[4].

Price Projections

Short-Term Projections

In the short term, prices for Moexipril HCL are expected to remain relatively stable, with minor fluctuations based on market competition and discount programs. The use of coupons and discount cards will continue to offer significant cost savings for patients.

Long-Term Projections

Long-term price projections indicate a potential decrease in prices due to increased competition from generic versions and other antihypertensive medications. The market is expected to grow, but the prices may stabilize or decrease slightly as more generic options become available and the market becomes more saturated[3].

Regional Market Analysis

Global Market

The global Moexipril HCL market is diverse, with different regions having varying levels of demand and supply. The market share and production capacity vary significantly across countries such as the USA, EU, Japan, and China. The Chinese market, in particular, is expected to play a significant role in the global supply and consumption of Moexipril HCL[4].

Key Markets

  • USA: The US market is one of the largest for Moexipril HCL, driven by a high prevalence of hypertension and a well-established healthcare system.
  • EU: The European market also shows significant demand, with a focus on both branded and generic versions of the medication.
  • China: China is emerging as a major player in the production and consumption of Moexipril HCL, driven by its large population and growing healthcare needs[4].

Industry Challenges and Opportunities

Challenges

  • Regulatory Hurdles: Changes in regulatory policies can impact the approval and distribution of Moexipril HCL.
  • Market Saturation: The increasing availability of generic versions and other antihypertensive medications can lead to market saturation and reduced prices.
  • Economic Factors: Economic instability can affect the affordability and accessibility of the medication[4].

Opportunities

  • Growing Demand: The increasing prevalence of hypertension globally presents a growing demand for effective antihypertensive medications like Moexipril HCL.
  • Expansion into New Markets: There is an opportunity for pharmaceutical companies to expand their market reach into emerging economies.
  • Innovative Delivery Systems: Developing innovative delivery systems or combination therapies can enhance the market position of Moexipril HCL[4].

Key Takeaways

  • Market Growth: The global Moexipril HCL market is expected to grow, reaching US$ 128.9 million by 2030.
  • Pricing: Prices can be significantly reduced using discount programs and coupons.
  • Market Dynamics: The market is influenced by supply and demand, economic factors, and regulatory policies.
  • Regional Analysis: The US, EU, and China are key markets for Moexipril HCL.
  • Challenges and Opportunities: The industry faces challenges such as regulatory hurdles and market saturation but also has opportunities for growth and innovation.

FAQs

What is Moexipril HCL used for?

Moexipril HCL is used primarily in the treatment of hypertension. It is an angiotensin-converting enzyme (ACE) inhibitor that helps lower blood pressure[2].

How much does Moexipril HCL cost?

The cost of Moexipril HCL can vary, but the typical cash price is around $48.19 to $94.19 per 30 tablets of 15mg each. However, using discount programs can reduce the cost to as low as $15.44[1][2].

Is Moexipril HCL available as a generic medication?

Yes, Moexipril HCL is available as a generic medication, which is significantly cheaper than the brand version, Univasc[1].

What are the potential side effects of Moexipril HCL?

Common side effects include cough, dizziness, and increased potassium levels. It is important to consult a healthcare provider for a full list of potential side effects[5].

Can Moexipril HCL be used in combination with other medications?

Yes, Moexipril HCL can be used in combination with other medications, such as the diuretic hydrochlorothiazide (as moexipril/hctz), to enhance its antihypertensive effects[2].

Sources

  1. SingleCare: Moexipril Hcl Coupons & Prices.
  2. GoodRx: Moexipril Prices, Coupons & Savings Tips.
  3. MarketResearchReports.com: Global Moexipril Market Research Report 2024.
  4. Prof-Research.com: Moexipril Hydrochloride Market Size, Share, Trend and Forecast to 2029.
  5. R&D Systems: Moexipril hydrochloride (CAS 82586-52-5).

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.